Cencora OUTPH Insights

1. When CGT Supply Chains Break Down: 5 Operational Gaps That Put Patient Outcomes At Risk 4/22/2026

   Examine five of the most consequential gaps in CGT supply chain performance and learn what high-functioning teams do differently to protect patient outcomes before a failure occurs.

2. Addressing A Critical Drug Shortage 4/20/2026

   A critical drug shortage demanded regulatory action, importation support, and patient program readiness. See how integrated QA, 3PL, and PSP capabilities delivered operational readiness in three months.

3. Foreign Action Notification To Health Canada 4/20/2026

   Health Canada is tightening foreign action reporting expectations. MAHs need to understand what the updated draft guidance means for their compliance and monitoring processes now.

4. Specialist PV Support Transforms Safety For Orphan Medicinal Products 4/17/2026

   Learn how a UK-based company developing two orphan-designated, centrally authorized therapies successfully navigated operational challenges after transitioning from a prior provider.

5. Boosting Quality And Reducing Complexity With A Single-Provider PV Solution 4/17/2026

   Discover how a German biopharmaceutical company successfully managed growing global pharmacovigilance complexity across more than 2,300 marketing authorizations and a broad partner network.

6. International Reference Pricing (IRP): Foundations, Shifts, And What To Do Next 4/17/2026

   As global pricing reforms evolve and policies gain traction, stakeholders must critically reassess the role of International Reference Pricing in balancing affordability, access, and incentives for innovation.

7. Streamlining European Expansion With Integrated PV, Regulatory, And Commercial Expertise 4/17/2026

   See how a single-provider model integrated pharmacovigilance with regulatory and commercialization support to support a scalable, audit-ready system that strengthened compliance and freed internal resources for growth.

8. Best Practices For Managing The Logistics And Distribution Of CGTs 2/23/2026

   Site infrastructure, formulary timelines, and storage capabilities create barriers between approval and patient access. Planning for these operational realities separates successful launches from stalled ones.

9. Navigating EU Regulatory Challenges With Cell And Gene Therapies 2/23/2026

   EU regulatory changes affecting advanced therapies demand new approaches to scientific advice, evidence generation, and health technology assessment for cell and gene therapy developers.

10. The Value Of Real-World Evidence In Canadian Drug Commercialization 2/18/2026

    Leveraging real-world evidence (RWE) across the product lifecycle enables manufacturers to fill the evidence gap beyond RCTs to help guide local commercial strategic planning and market access strategy.